CDK4 and cancer: However, with data suggesting that mechanisms of resistance to CDK4/6 inhibitors seem uniform between the different agents, the higher odds of non-cancer deaths with abemaciclib relative to placebo compared to other CDK4/6 inhibitors is an important observation27.